glp-1 medications approved for type 2 diabetes 2025 Pipeline Update: February - Prime Therapeutics GLP-1 Medications Infographic | Medidex

The International Association for the Study of Pain defines it as pain resulting from a stimulus that does not normally provoke pain, and that definition matters because it distinguishes allodynia from hyperalgesia, where painful stimuli simply hurt more than expected

doi:10.1016/j.physbeh.2011.01.012 64

GLP-1RAs increase natriuresis by inhibiting sodium reabsorption by acting on the Na/H exchanger in the proximal tubule of the kidney [75]

This, in turn, stimulates downstream signaling elements dependent on both protein kinase A (PKA) and exchange protein directly activated by cAMP (EPAC) activation, which triggers the opening of voltage-dependent calcium channels (VDCCs), resulting in insulin exocytosis [24, 25]